Oncolytics Biotech Inc. announced a strategic update on its intellectual property portfolio for its lead immunotherapy candidate, pelareorep. The company has secured new method of use patents and is developing a next-generation version, aiming to extend patent protection for its key asset into the late 2040s.
Key Details
- New Patents: A new method of use patent for pelareorep as a cancer immunotherapy has been issued in several countries, with a corresponding U.S. patent expected to be issued in the near term.
- Extended Protection: These initiatives build upon existing manufacturing patent protection through 2044 and are intended to extend therapeutic use protection into the late 2040s.
- Future Development: The company is developing a "next generation" modified pelareorep, which is expected to support a new composition of matter patent. Additionally, one of three pending applications will be converted to a prioritized "Track One" U.S. application this quarter for accelerated review.